Dianthus Therapeutics is a clinical-stage biotechnology company specializing in the development of advanced monoclonal antibodies designed to address severe autoimmune and inflammatory diseases. The company is headquartered in New York City and Waltham, Massachusetts, and is driven by a team of experienced professionals from the biotech and pharmaceutical industries. Dianthus is dedicated to creating next-generation antibody complement therapeutics that aim to provide transformative treatment options for patients suffering from complex health conditions. With a commitment to scientific integrity and innovation, Dianthus values collaboration, transparency, and excellence in its operations and research. This culture fosters continuous improvement and empowers employees to contribute meaningfully to the mission of enhancing patient care.